A 52-Week, Open-Label, Long-Term Safety Study of LY2189265 in Combination With Monotherapy of Oral Antihyperglycemic Medications in Patients With Type 2 Diabetes Mellitus
Phase 3
Recruiting
- Conditions
- Type 2 Diabetes Mellitus
- Registration Number
- JPRN-jRCT2080221664
- Lead Sponsor
- Eli Lilly Japan K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients who have had a diagnosis of type 2 diabetes mellitus before screening
Patients who have been taking SU (Glibenclamide, Gliclazide, Glimepiride), biguanides, TZD, a-GI or glinides monotherapy for at least 3 months before screening and have been on a stable dose for at least 8 weeks before screening
Patients must have a qualifying HbA1c value of 7.0% to 11.0% at screening
Patients who have a body mass index (BMI) of 18.5 kg/m2 to 35.0 kg/m2
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method